ResearchMoz

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2013

GlobalData
Published Date » 2013-11-30
No. Of Pages » 159
 GlobalData's Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals Q3 2013 report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on partnerships, licensing agreements, M&As, equity/debt offerings, private equity and venture financing transactions recorded in the pharmaceutical and healthcare industry in Q3 2013. The report presents detailed comparative data on the number of deals and their value in the last five quarters, categorized into deal types, segments, and geographies. The report also provides information on the top venture capital and advisory firms in the pharmaceutical and...
Table of Contents

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 11

2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q3 2013 15
2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q3 2013 15
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q3 2013 17
2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q3 2013 18
2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2013 19
2.4.1 Shoppers Drug Mart Receives Ontario Court Approval for Its Acquisition by Loblaw for US$11.93 Billion 19
2.4.2 Amgen Completes Tender Offer to Acquire Onyx Pharma for up To US$10.4 Billion 21
2.4.3 Community Health Systems to Acquire Health Management Associates for up to US$7.6 Billion 22
2.4.4 Fresenius to Acquire 43 Hospitals from Rhon-Klinikum for US$4.1 Billion 23
2.4.5 Tenet Healthcare Prices Private Placement of Notes Due 2022 for US$2.8 Billion 24

3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 25
3.1 Pharmaceuticals & Healthcare, Global, M&A, Q3 2013 25
3.1.1 Top M&A Deals in Q3 2013 26
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q3 2012 - Q3 2013 27
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q3 2013 29
3.2.1 Top Initial Public Offerings in Q3 2013 31
3.2.2 Top Secondary Offerings in Q3 2013 31
3.2.3 Top PIPE Deals in Q3 2013 31
3.2.4 Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q3 2012-Q3 2013 32
3.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q3 2012 - Q3 2013 33
3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q3 2013 35
3.3.1 Top Venture Financing Deals in Q3 2013 36
3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2013 37
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2013 38
3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q3 2012 - Q3 2013 39
3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Last Four Quarters 41
3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2012 - Q3 2013 43
3.4 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q3 2013 44
3.4.1 Top Private Equity Deals in Q3 2013 45
3.4.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q3 2012 - Q3 2013 46

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2013 48
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2013 48
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q3 2012 - Q3 2013 50
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2013 52
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q3 2013 54
4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2013 54
4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q3 2013 55
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 - Q3 2013 56
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q3 2012 - Q3 2013 58
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q3 2012 - Q3 2013 59
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 - Q3 2013 61

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q3 2013 63
5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q3 2013 63
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 - Q3 2013 65
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q3 2013 67
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q3 2013 67
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q3 2013 68
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q3 2012 - Q3 2013 69
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q3 2012 - Q3 2013 71
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2012 - Q3 2013 73
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2012 - Q3 2013 74
5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q3 2012 - Q3 2013 76

6 Pharmaceuticals & Healthcare, Global, M&A Financial Analysis 78
6.1 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q3 2012 - Q3 2013 78
6.2 Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q3 2012 - Q3 2013 80
6.3 Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2012 - Q3 2013 82
6.4 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q3 2012 - Q3 2013 84
6.5 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q3 2012 - Q3 2013 86
6.6 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Book Value Per Share, Q3 2012 - Q3 2013 88
6.7 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2012 - Q3 2013 90

7 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 92
7.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q3 2013 92
7.1.1 Oncology - Deals of the Quarter 94
7.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q3 2013 96
7.2.1 Central Nervous System - Deals of the Quarter 98
7.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q3 2013 101
7.3.1 Infectious Disease - Deals of the Quarter 103
7.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q3 2013 105
7.4.1 Immunology - Deals of the Quarter 107
7.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q3 2013 108
7.5.1 Metabolic Disorders - Deals of the Quarter 110
7.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q3 2013 112
7.6.1 Cardiovascular - Deals of the Quarter 114
7.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q3 2013 116
7.7.1 Gastrointestinal - Deals of the Quarter 118
7.8 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q3 2013 119
7.8.1 Dermatology - Deals of the Quarter 121
7.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q3 2013 122
7.9.1 Respiratory - Deals of the Quarter 124
7.10 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q3 2013 126
7.10.1 Ophthalmology - Deals of the Quarter 128

8 Deal Summary by Geography 130
8.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q3 2013 130
8.1.1 North America - Deals of the Quarter 132
8.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q3 2013 135
8.2.1 Europe - Deals of the Quarter 137
8.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q3 2013 139
8.3.1 Asia-Pacific - Deals of the Quarter 141
8.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q3 2013 144
8.4.1 Rest of the World - Deals of the Quarter 146

9 Pharmaceuticals & Healthcare, Global, Top Advisors 148
9.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Last One Year 148
9.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Last One Year 150

10 Appendix 152

11 Further Information 156
11.1 Methodology 156
11.2 About GlobalData 157
11.3 Disclosure information 158
11.4 Disclaimer 158

List of Tables


Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q3 2012 - Q3 2013 16
Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q3 2013 19
Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2013 19
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 26
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q3 2013 26
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q3 2012 - Q3 2013 28
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2012 - Q3 2013 30
Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q3 2013 31
Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q3 2013 31
Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q3 2013 31
Table 11: Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q3 2012-Q3 2013 32
Table 12: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2012 - Q3 2013 34
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 36
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q3 2013 36
Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number of Deals and Deal Values (%), Q3 2013 38
Table 16: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2012 - Q3 2013 40
Table 17: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q4 2012 - Q3 2013 42
Table 18: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2012 - Q3 2013 43
Table 19: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 45
Table 20: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q3 2013 45
Table 21: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2012 - Q3 2013 47
Table 22: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 49
Table 23: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 51
Table 24: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 - Q3 2013 53
Table 25: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2013 54
Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2013 54
Table 27: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q3 2013 55
Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2012 - Q3 2013 57
Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2012 - Q3 2013 60
Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2012 - Q3 2013 62
Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 64
Table 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 - Q3 2013 66
Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q3 2013 67
Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q3 2013 67
Table 35: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q3 2013 68
Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 70
Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q3 2012 - Q3 2013 72
Table 38: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2012 - Q3 2013 75
Table 39: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2012 - Q3 2013 77
Table 40: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q3 2012 - Q3 2013 79
Table 41: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q3 2012 - Q3 2013 81
Table 42: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2012 - Q3 2013 83
Table 43: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Operating Profit, Q3 2012 - Q3 2013 85
Table 44: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q3 2012 - Q3 2013 87
Table 45: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q3 2012 - Q3 2013 89
Table 46: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2012 - Q3 2013 91
Table 47: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 93
Table 48: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 97
Table 49: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 102
Table 50: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 106
Table 51: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 109
Table 52: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 113
Table 53: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 117
Table 54: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 120
Table 55: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 123
Table 56: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 127
Table 57: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 131
Table 58: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 136
Table 59: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 140
Table 60: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 145
Table 61: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q4 2012 - Q3 2013 149
Table 62: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q4 2012 - Q3 2013 151
Table 63: Pharmaceuticals & Healthcare, Deals’ Key Financials, Global Acquisition Deals, Q3 2012-Q3 2013 152

List of Figures


Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q3 2012 - Q3 2013 15
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q3 2013 17
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q3 2013 18
Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q3 2012 - Q3 2013 25
Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q3 2012 - Q3 2013 27
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 29
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q3 2012 - Q3 2013 33
Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 35
Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q3 2013 37
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q3 2013 38
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q3 2012 - Q3 2013 39
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q4 2012 - Q3 2013 41
Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 44
Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q3 2012 - Q3 2013 46
Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 48
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 50
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2012 - Q3 2013 52
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2012 - Q3 2013 56
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2012 - Q3 2013 58
Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2012 - Q3 2013 59
Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2012 - Q3 2013 61
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 63
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 - Q3 2013 65
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 69
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 - Q3 2013 71
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q3 2012 - Q3 2013 73
Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q3 2012 - Q3 2013 74
Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 - Q3 2013 76
Figure 29: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q3 2012 - Q3 2013 78
Figure 30: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q3 2012 - Q3 2013 80
Figure 31: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2012 - Q3 2013 82
Figure 32: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q3 2012 - Q3 2013 84
Figure 33: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q3 2012 - Q3 2013 86
Figure 34: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q3 2012 - Q3 2013 88
Figure 35: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2012 - Q3 2013 90
Figure 36: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 92
Figure 37: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 96
Figure 38: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 101
Figure 39: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 105
Figure 40: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 108
Figure 41: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 112
Figure 42: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 116
Figure 43: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 119
Figure 44: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 122
Figure 45: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 126
Figure 46: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 130
Figure 47: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 135
Figure 48: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 139
Figure 49: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 144
Figure 50: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q4 2012 - Q3 2013 148
Figure 51: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q4 2012 - Q3 2013 150

Upcoming Reports:

Cardiac Assist Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Cardiac Assist Devices (CAD) are type of mechanical pumps that work along with the heart to improve its pumping efficiency and maintain the optimum blood flow throughout the body. Cardiac Assist Devices can be segmented in three types ventricular assist devices, intra-aortic balloon pumps (IABPs) and total artificial heart. Ventricular assist device (VAD) is a mechanical pump which takes blood from a lower chamber of the heart and pumps it to the body and vital organs. Ventricular devices are of two types right ventricular assist device (RVAD), left ventricular assist device...
Pharmacogenomics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
By - Transparency Market Research
Pharmacogenomics deals with the study of inherited variations in human genes that affect an individual’s reaction to a particular drug. It co-integrates the genetic sciences with pharmaceutical science. Thus, it is the science of individualizing the drug, which is based on individual’s genetic makeup. And, many times pharmacogenomics are linked to personalized medicine, as the environmental conditions, genetic variations, and changing lifestyle greatly influence the type and severity of diseases as well as therapeutic responses that varies from person to person. In...
Dental Prosthetics Market - Global Industry Size, Market Share, Trends, Analysis And Forecasts 2012 - 2018
By - Transparency Market Research
Growing edentulousness and rising rates of oral diseases boosts the demand for dental prostheses worldwide. Dental prostheses are artificial tooth replacements used in case of tooth loss. Complete dentition is necessary for a healthy lifestyle and dental prostheses help restore the function of lost teeth. The market for dental prosthetics holds a major share in the dental consumables market, with each segment serving the growing edentulous and aged population, across the globe. The market is mainly segmented into crowns & bridges, dentures, artificial teeth, and implants....

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Illinois Voicing for Funds to Promote Clean Energy Plants
Mar 26, 2015  
The advocates of renewable energy has been voicing for overhaul of the Illinois’s clean energy law for several years in a row. Refurbishing the law would entail a release of over $100 million that was collected as ratepayer charges that they can invest on payment for new solar and wind projects. However, the proponents could not help the cause and now it seems that the state is...
Michigan To Capitalize on Clean and Local Energy
Mar 26, 2015  
For years now Americans have been campaigning to promote “eat locally and shop locally” culture. Inspired from the drive, Michiganders have got on board the plan to locally harness the energy to power their lives.  It will be very interesting to see how Gov. Rick Snyder’s vision of “no-regret energy future”, which has its key focus on curbing the...
Noble Energy Pulls Out from Ruth C License Exploration
Mar 26, 2015  
Citing issues related to “regulatory uncertainty”, in the energy and gas sector of Israel, the Houston-based company named Noble Energy forwent with its permit for operation in the Ruth C exploration license, as reported by Tel Aviv Stock Exchange on Thursday.  The Ruth C license zone is located off the Haifa coast, to the east of the larger Tamar basin. Energy reserve...
Leaders Go Back to School to Motive Students to Join the Construction Industry
Mar 26, 2015  
The housing sector is facing a major shortage in UK as the region suffers from lack of skilled construction workers. Amidst this crisis, two of the industry leaders are touring schools to encourage students to be a part of the industry which so desperately needs them. According to the Construction Industry Training Board, UK needs a workforce of 180,000 or more with adequate skill sets...
Israel Freezes Construction of 1,500 New Housing Units
Mar 26, 2015  
Israel has scrapped the plan to build 1,500 new housing units in East Jerusalem. The decision comes despite Prime Minister Benjamin Netanyahu's announcement to continue construction regardless of international pressure. East Jerusalem is the neighboring region of Har Homa, a little beyond the Green Line.  From the looks of it, the construction plan in Har Homa seems to have been...